AnaptysBio stock drops on malignancy concerns with Eli Lilly’s PD-1 agonist
NegativeFinancial Markets

AnaptysBio's stock has taken a hit due to rising concerns over malignancy linked to Eli Lilly's PD-1 agonist. This news is significant as it raises questions about the safety of new cancer treatments, potentially impacting investor confidence and the future of similar therapies in development.
— Curated by the World Pulse Now AI Editorial System